| Literature DB >> 33227715 |
Harald Paganetti1,2, Chris Beltran3, Stefan Both4, Lei Dong5, Jacob Flanz1,2, Keith Furutani3, Clemens Grassberger1,2, David R Grosshans6, Antje-Christin Knopf4, Johannes A Langendijk4, Hakan Nystrom7,8, Katia Parodi9, Bas W Raaymakers10, Christian Richter11,12,13, Gabriel O Sawakuchi14, Marco Schippers15, Simona F Shaitelman6, B K Kevin Teo5, Jan Unkelbach16, Patrick Wohlfahrt1, Tony Lomax15.
Abstract
The treatment of cancer with proton radiation therapy was first suggested in 1946 followed by the first treatments in the 1950s. As of 2020, almost 200 000 patients have been treated with proton beams worldwide and the number of operating proton therapy (PT) facilities will soon reach one hundred. PT has long moved from research institutions into hospital-based facilities that are increasingly being utilized with workflows similar to conventional radiation therapy. While PT has become mainstream and has established itself as a treatment option for many cancers, it is still an area of active research for various reasons: the advanced dose shaping capabilities of PT cause susceptibility to uncertainties, the high degrees of freedom in dose delivery offer room for further improvements, the limited experience and understanding of optimizing pencil beam scanning, and the biological effect difference compared to photon radiation. In addition to these challenges and opportunities currently being investigated, there is an economic aspect because PT treatments are, on average, still more expensive compared to conventional photon based treatment options. This roadmap highlights the current state and future direction in PT categorized into four different themes, 'improving efficiency', 'improving planning and delivery', 'improving imaging', and 'improving patient selection'.Entities:
Keywords: dosimetry; imaging; proton radiation therapy
Mesh:
Year: 2021 PMID: 33227715 PMCID: PMC9275016 DOI: 10.1088/1361-6560/abcd16
Source DB: PubMed Journal: Phys Med Biol ISSN: 0031-9155 Impact factor: 4.174